Tao Yukari, Maegawa Hiroshi, Ugi Satoshi, Ikeda Kazuhiro, Nagai Yoshio, Egawa Katsuya, Nakamura Takaaki, Tsukada Shuichi, Nishio Yoshihiko, Maeda Shiro, Kashiwagi Atsunori
Division of Endocrinology and Metabolism, Department of Medicine, Shiga University of Medical Science, Seta, Otsu, Japan.
Endocrinology. 2006 Apr;147(4):1685-96. doi: 10.1210/en.2005-1304. Epub 2005 Dec 22.
We have reported the association of variations in the activating protein-2beta (AP-2beta) transcription factor gene with type 2 diabetes. This gene was preferentially expressed in 3T3-L1 adipocytes in a differentiation stage-dependent manner, and preliminary experiments showed that subjects with the disease-susceptible allele showed stronger expression in adipose tissue than those without the susceptible allele. Thus, we overexpressed the AP-2beta gene in 3T3-L1 adipocytes to clarify whether AP-2beta might play a crucial role in the pathogenesis of type 2 diabetes through dysregulation of adipocyte function. In cells overexpressing AP-2beta, cells increased in size by accumulation of triglycerides accompanied by enhanced glucose uptake. On the contrary, suppression of AP-2beta expression by small interfering RNA inhibited glucose uptake. Enhancement of glucose uptake by AP-2beta overexpression was attenuated by inhibitors of phospholipase C (PLC) and atypical protein kinase Czeta/lambda (PKCzeta/lambda), but not by a phosphatidylinositol 3-kinase (PI3-K) inhibitor. Consistently, we found activation of PLC and atypical PKC, but not PI3-K, by AP-2beta expression. Furthermore, overexpression of PLCgamma enhanced glucose uptake, and this activation was inhibited by an atypical PKC inhibitor, suggesting that the enhanced glucose uptake may be mediated through PLC and atypical PKCzeta/lambda, but not PI3-K. Moreover, we observed the increased tyrosine phosphorylation of Grb2-associated binder-1 (Gab1) and its association with PLCgamma, indicating that Gab1 may be involved in AP-2beta-induced PLCgamma activation. Finally, AP-2beta overexpression was found to relate to the impaired insulin signaling. We propose that AP-2beta is a candidate gene for producing adipocyte hypertrophy and may relate to the abnormal characteristics of adipocytes observed in obesity.
我们已经报道了激活蛋白-2β(AP-2β)转录因子基因变异与2型糖尿病的关联。该基因在3T3-L1脂肪细胞中以分化阶段依赖性方式优先表达,初步实验表明,携带疾病易感等位基因的受试者在脂肪组织中的表达比没有易感等位基因的受试者更强。因此,我们在3T3-L1脂肪细胞中过表达AP-2β基因,以阐明AP-2β是否可能通过脂肪细胞功能失调在2型糖尿病发病机制中发挥关键作用。在过表达AP-2β的细胞中,细胞因甘油三酯积累而增大,同时葡萄糖摄取增强。相反,小干扰RNA抑制AP-2β表达则抑制葡萄糖摄取。磷脂酶C(PLC)和非典型蛋白激酶Cζ/λ(PKCζ/λ)抑制剂可减弱AP-2β过表达对葡萄糖摄取的增强作用,但磷脂酰肌醇3-激酶(PI3-K)抑制剂则无此作用。一致地,我们发现AP-2β表达可激活PLC和非典型PKC,但不激活PI3-K。此外,PLCγ过表达增强葡萄糖摄取,且这种激活被非典型PKC抑制剂抑制,提示增强的葡萄糖摄取可能通过PLC和非典型PKCζ/λ介导,而非PI3-K。此外,我们观察到Grb2相关结合蛋白-1(Gab1)的酪氨酸磷酸化增加及其与PLCγ的结合,表明Gab1可能参与AP-2β诱导的PLCγ激活。最后,发现AP-2β过表达与胰岛素信号受损有关。我们提出,AP-2β是导致脂肪细胞肥大的候选基因,可能与肥胖中观察到的脂肪细胞异常特征有关。